FindTrial
Sign In

E7386

DRUG8 trials

Sponsors

Eisai Limited, Eisai Inc., Eisai Co., Ltd.

Conditions

Advanced NeoplasmsCarcinoma, HepatocellularColorectal NeoplasmsEndometrial NeoplasmsFood Effect in Healthy ParticipantsGastrointestinal TumorsHealthy VolunteersHepatocellular carcinoma

Phase 1

Study of E7386 in Participants With Selected Advanced Neoplasms
Active, not recruitingNCT03264664
Eisai Inc.Advanced Neoplasms
Start: 2017-07-27End: 2027-03-31Target: 60Updated: 2026-03-06
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
Active, not recruitingNCT03833700
Eisai Co., Ltd.Colorectal Neoplasms, Gastrointestinal Tumors, Solid Neoplasms
Start: 2019-03-05End: 2027-03-31Target: 70Updated: 2026-02-27
A Food-Effect Study of E7386 in Healthy Participants
CompletedNCT03996226
Eisai Inc.Food Effect in Healthy Participants
Start: 2019-06-07End: 2019-10-29Updated: 2019-11-14
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Active, not recruitingNCT04008797
Eisai Inc.Carcinoma, Hepatocellular, Colorectal Neoplasms, Endometrial Neoplasms +2
Start: 2019-07-11End: 2027-03-31Target: 301Updated: 2026-03-24
A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants
WithdrawnNCT04840927
Eisai LimitedHealthy Volunteers
Start: 2021-04-09End: 2023-05-17Updated: 2023-11-24
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
CompletedNCT05091346
Eisai Inc.Carcinoma, Hepatocellular, Colorectal Neoplasms, Melanoma
Start: 2021-10-27End: 2024-10-15Updated: 2025-10-24
An Open-Label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
Active, not recruitingCTIS2023-510275-64-00
Eisai Limitedcolorectal cancer, endometrial cancer, Hepatocellular carcinoma +1
Start: 2023-05-31Target: 83Updated: 2025-11-07
An open-label, multicenter, phase 1b/2 study of E7386 in combination with pembrolizumab in previously treated subjects with selected solid tumors
CompletedCTIS2023-505425-14-00
Eisai Limitedcolorectal cancer, hepatocellular carcinoma, melanoma
Start: 2022-08-11End: 2024-10-15Target: 30Updated: 2024-09-30

Related Papers

Abstract 7171: Antitumor and antiangiogenic activities of E7386 in combination with lenvatinib in human endometrial carcinoma xenograft models
Cancer Research2026-04-03
E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma.
2025-12-01
Data from E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma
2025-12-01
E7386 study 102: Global dose-expansion cohort of E7386 + lenvatinib (LEN) in patients (pts) with advanced endometrial cancer (aEC) that progressed on platinum-based chemotherapy (chemo) and an anti-PD-(L)1 immunotherapy (IO).
Journal of Clinical Oncology2025-05-28
Randomized study evaluating optimal dose, efficacy and safety of E7386 + lenvatinib versus treatment of physicians’ choice in advanced/recurrent endometrial carcinoma previously treated with anti–PD-(L)1 immunotherapy.
Journal of Clinical Oncology2025-05-28
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician’s choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors
International Journal of Gynecological Cancer2025-04-06
Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC).
Journal of Clinical Oncology2024-06-012 citations
Abstract 2026: Single-cell RNA-sequencing analysis of tumor endothelial cells reveals suppression of specific endothelial subtypes by the combination treatment of Wnt/β-catenin signaling modulator E7386 plus lenvatinib
Cancer Research2024-03-22
Analysis of tumor biomarkers in patients (pts) with advanced hepatocellular carcinoma (HCC) from a phase 1b study of E7386, a CREB-binding protein/β-catenin interaction inhibitor, in combination with lenvatinib.
Journal of Clinical Oncology2024-01-202 citations
A phase 1b study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients with advanced hepatocellular carcinoma.
Journal of Clinical Oncology2023-06-014 citations
Abstract 1830: E7386, a selective inhibitor of the interaction between β-catenin and CREB-binding protein (CBP), in combination with lenvatinib (LEN), exerts antitumor activity in preclinical tumor models with prior immune checkpoint inhibitor (ICI)-based combination treatment
Cancer Research2023-04-04
A phase 1 study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in patients (pts) with advanced solid tumors including colorectal cancer: Updated dose-escalation part.
Journal of Clinical Oncology2023-01-245 citations
Abstract CT523: An open-label, multicenter, phase 1b/2 Study of E7386 (Wnt/β-catenin pathway inhibitor) + pembrolizumab in patients with pretreated advanced solid tumors
Cancer Research2022-06-152 citations
Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503).
2020-08-0116 citations